Viktor Lemmens

Viktor Lemmens

Auto-generated profile, based on publicly available information

Viktor Lemmens

KU Leuven, Rega Institute, Department of Microbiology, Immunology and Transplantation, Antiviral Drug and Vaccine Research Group, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Nature
Verified
Journal Article
Closed access
PDF file
LSLorena Sanchez-Felipe
Lorena Sanchez-Felipe
TVThomas Vercruysse
Thomas Vercruysse
SSSapna Sharma
Sapna Sharma
JMJi Ma
Ji Ma
VLViktor Lemmens
Viktor Lemmens
KDKai Dallmeier
Kai Dallmeier

4 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSSapna Sharma
Sapna Sharma
TVThomas Vercruysse
Thomas Vercruysse
LSLorena Sanchez-Felipe
Lorena Sanchez-Felipe
WKWinnie Kerstens
Winnie Kerstens
MRMadina Rasulova
Madina Rasulova
KDKai Dallmeier
Kai Dallmeier
Current COVID-19 vaccines are based on prototypic spike sequences from ancestral 2019 SARS-CoV-2 strains. However, the ongoing pandemic is fueled by variants of concern (VOC) escaping vaccine-mediated protection. Here we demonstrate how immunization in hamsters using prototypic spike expressed from yellow fever 17D (YF17D) as vector blocks ancestral virus (B lineage) and VOC Alpha (B.1.1.7) yet fails to fully protect from Beta (B.1.351). However, the same YF17D vectored vaccine candidate with an evolved antigen induced considerably improved neutralizing antibody responses against VOCs Beta, Gamma (P.1) and the recently predominant Omicron (B.1.1.529), while maintaining immunogenicity against ancestral virus and VOC Delta (B.1.617.2). Thus vaccinated animals resisted challenge by all VOCs, including vigorous high titre exposure to the most difficult to cover Beta, Delta and Omicron variants, eliminating detectable virus and markedly improving lung pathology. Finally, vaccinated hamsters did not transmit Delta variant to non-vaccinated cage mates. Overall, our data illustrate how current first-generation COVID-19 vaccines may need to be updated to maintain efficacy against emerging VOCs and their spread at community level.

11 July 2023 in npj Vaccines
Verified
Journal Article
Open access
PDF file
VLViktor Lemmens
Viktor Lemmens
LKLara Kelchtermans
Lara Kelchtermans
SDSarah Debaveye
Sarah Debaveye
WCWinston Chiu
Winston Chiu
TVThomas Vercruysse
Thomas Vercruysse
KDKai Dallmeier
Kai Dallmeier
Ebola virus (EBOV) and related filoviruses such as Sudan virus (SUDV) threaten global public health. Effective filovirus vaccines are available only for EBOV, yet restricted to emergency use considering a high reactogenicity and demanding logistics. Here we present YF-EBO, a live YF17D-vectored dual-target vaccine candidate expressing EBOV glycoprotein (GP) as protective antigen. Safety of YF-EBO in mice was further improved over that of parental YF17D vaccine. A single dose of YF-EBO was sufficient to induce high levels of EBOV GP-specific antibodies and cellular immune responses, that protected against lethal infection using EBOV GP-pseudotyped recombinant vesicular stomatitis virus (rVSV-EBOV) in interferon-deficient (Ifnar-/-) mice as surrogate challenge model. Concomitantly induced yellow fever virus (YFV)-specific immunity protected Ifnar-/- mice against intracranial YFV challenge. YF-EBO could thus help to simultaneously combat both EBOV and YFV epidemics. Finally, we demonstrate how to target other highly pathogenic filoviruses such as SUDV at the root of the 2022 outbreak in Uganda.

13 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
VLViktor Lemmens
Viktor Lemmens
LKLara Kelchtermans
Lara Kelchtermans
SDSarah Debaveye
Sarah Debaveye
WCWinston Chiu
Winston Chiu
TVThomas Vercruysse
Thomas Vercruysse
KDKai Dallmeier
Kai Dallmeier
Ebola virus (EBOV) and related filoviruses such as Sudan virus (SUDV) threaten global public health. Effective filovirus vaccines are available only for EBOV, yet restricted to emergency use considering a high reactogenicity and demanding logistics. Here we present YF-EBO, a live YF17D-vectored dual-target vaccine candidate expressing EBOV-glycoprotein (GP) as protective antigen. Safety of YF-EBO in mice was further improved over that of parental YF17D vaccine. A single dose of YF-EBO was sufficient to induce high levels of EBOV-GP specific antibodies and cellular immune responses, that protected against lethal infection using EBOV-GP-pseudotyped recombinant vesicular stomatitis virus (rVSV-EBOV) in interferon-deficient ( Ifnar -/- ) mice as surrogate challenge model. Concomitantly induced yellow fever virus (YFV)-specific immunity protected Ifnar -/- mice against intracranial YFV challenge. YF-EBO could thus help to simultaneously combat both EBOV and YFV epidemics. Finally, we demonstrate how to target other highly pathogenic filoviruses such as SUDV at the root of a current outbreak in Uganda.

26 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MYMichael B. Yakass
Michael B. Yakass
SJSander Jansen
Sander Jansen
VLViktor Lemmens
Viktor Lemmens
LSLorena Sanchez-Felipe
Lorena Sanchez-Felipe
JNJohan Hendrik Neyts
Johan Hendrik Neyts
KDKai Dallmeier
Kai Dallmeier
SUMMARY: Tracking of viral replication and tissue tropism by in vivo imaging can help to unveil how live-attenuated vaccines such as the yellow fever 17D (17D) work, and likewise, to understand how adverse effects develop. Here we validate 17D-TK, a reporter virus derived from 17D that expresses herpes virus thymidine kinase (TK) that specifically converts nucleoside analogues such as Ganciclovir (GCV) to induce cell death, or difluoro-EdU (dF-EdU) for bioorthogonal labelling of infected cells by Click chemistry. 17D-TK induces a cytopathic effect in infected cell cultures, as well as mortality in intracranially inoculated mouse pups in a GCV dependent manner. Preferential phosphorylation of difluoro-EdU (dF-EdU) in 17D-TK infected cells allows to selectively stain cells that support 17D replication. Prospectively, 17D-TK can be used in combination with radiolabeled tracers for real-time detection and localization of sites of active viral replication in living animals using positron emission tomography (PET).

31 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JVJens Verlinden
Jens Verlinden
JSJoren Stroobants
Joren Stroobants
JNJesus Sacramento Nonay
Jesus Sacramento Nonay
CWCharlotte Willems
Charlotte Willems
KGKato Govaerts
Kato Govaerts
BVBert Vanmechelen
Bert Vanmechelen
Filoviruses, particularly those of the Orthoebolavirus genus, pose ongoing public health threats due to their increasing frequency and geographic spread. However, research has been impeded by the biosafety level 4 classification of filoviruses. We previously reported the generation of biologically contained Ebola, Marburg and Sudan virus as lower biosafety level-compatible filovirus systems. In the present study, we expanded this repertoire to include biologically contained Taï Forest, Bundibugyo and Reston virus, thereby creating a near-complete toolkit for currently recognized human-relevant orthoebolaviruses. VP30-deficient viruses were generated with matching VP30 expressing cell lines. More specifically, we developed and optimized a dual-reporter system in VeroE6, Huh-7 and A549 cells, combining a virus-encoded enhanced green fluorescent protein reporter as readout for viral replication with a stably cellular-expressed nuclear mCherry marker for cytotoxicity assessment. Next, we screened two repurposing-oriented compound libraries comprising 640 small molecules against Taï Forest, Bundibugyo and Sudan virus, and subsequently cross-validated against Reston and Ebola virus. This approach identified multiple candidates with broad-spectrum activity across orthoebolaviruses, while also revealing virus-specific antivirals, with robust activity observed in both primate- and human-derived cell lines. Together, this work establishes a versatile and experimentally tractable lower biosafety level-compatible platform for the study of human-relevant orthoebolaviruses and the systematic discovery of broad-spectrum antiviral countermeasures against filoviruses.